

Report of Head and Neck Cancer Registry of Japan Five-year Prognosis of Patients Registered in 2011

Japan Society for Head and Neck Cancer
Cancer Registry Committee

Primary tumor site	Number of patients	%
1) Oral cavity	1062	31
2) Nasal cavity, etc.	205	6
3) Nasopharynx	103	3
4) Oropharynx	522	15
5) Hypopharynx	697	21
6) Larynx	633	19
7) Major salivary glands	159	5
Total	3381	100

Nasal cavity, etc.: nasal cavity and paranasal sinuses

	MFT to relapse (month; range)	MFT to death or last follow-up (month)
1) Oral cavity	6.5 (0.2-79.3)	57.5
2) Nasal cavity, etc.	9.1 (0.6-73.1)	25.6
3) Nasopharynx	16.6 (4.4-79.0)	64.4
4) Oropharynx	10.4 (0.2-74.9)	54.9
5) Hypopharynx	9.6 (0.4-86.9)	35.5
6) Larynx	10.0 (0.03-84.6)	61.2
7) Major salivary glands	12.9 (2.0-80.6)	62.3

Nasal cavity, etc.: nasal cavity and paranasal sinuses

*Abbreviation: MFT; Median follow-up time.

	1) Oral cavity	2) Nasal cavity, etc.	3) Nasopharynx	4) Oropharynx	5) Hypopharynx	6) Larynx	7) Major salivary glands
Relapse lesion	Number of Patients (Number of DOD)						
No	660 (7)	93 (8)	59 (1)	320 (4)	388 (8)	480 (2)	89 (3)
Local	118 (52)	41 (16)	13 (8)	49 (24)	55 (14)	54 (11)	8 (0)
Regional	122 (49)	12 (8)	5 (4)	42 (20)	76 (47)	35 (17)	11 (5)
Distant	51 (37)	17 (13)	7 (5)	30 (25)	73 (47)	24 (17)	36 (22)
Local+Regional	15 (11)	1 (1)	1 (1)	13 (7)	5 (2)	4 (0)	1 (1)
Local+Distant	6 (5)	6 (4)	0 (0)	3 (1)	2 (2)	0 (0)	0 (0)
Regional+Distant	19 (15)	3 (3)	4 (4)	5 (4)	14 (8)	7 (5)	1 (1)
Local+Regional+Distant	5 (4)	0 (0)	0 (0)	4 (3)	4 (1)	2 (2)	2 (1)
Undecidable	50 (39)	24 (13)	13 (6)	48 (27)	73 (43)	18 (10)	9 (8)
Unknown	16 (1)	8 (2)	1 (0)	8 (1)	7 (2)	9 (1)	2 (1)
Total	1062 (220)	205 (68)	103 (29)	522 (116)	697 (174)	633 (65)	159 (42)

Nasal cavity, etc.: nasal cavity and paranasal sinuses

*Abbreviation: DOD; Death of Disease.

	1) Oral cavity	2) Nasal cavity, etc.	3) Nasopharynx	4) Oropharynx	5) Hypopharynx	6) Larynx	7) Major salivary glands
Disease stage	Median follow-up time to death or last follow-up (month)						
0	63.3	-	-	71.9	67.8	74.3	-
1	66.2	50.8	50.2	75.1	62.5	64.9	75.0
2	61.2	60.9	64.6	63.6	72.6	62.7	75.2
3	60.4	40.5	71.6	61.4	52.4	61.5	66.5
4a	29.0	13.2	63.6	54.6	25.0	47.6	42.6
4b	13.2	15.8	79.1	24.5	18.4	10.6	79.6
4c	3.6	9.9	10.5	7.7	8.2	9.3	14.4
Unknown	20.4	53.7	14.4	31.3	24.0	62.9	50.3

Nasal cavity, etc.: nasal cavity and paranasal sinuses

Number of metachronous multiple cancer by primary tumor site (first / second)

	No	Head and Neck	Esophagus	Lung	Stomach	Liver	Colon	Others	Unknown	Total
1) Oral cavity	391/406	29/28	17/12	8/9	10/15	4/2	11/5	17/17	4/7	590/572
2) Nasal cavity, etc.	56/58	1/1	1/1	0/1	2/0	0/2	1/2	6/2	2/2	138/137
3) Nasopharynx	38/39	0/0	1/0	0/2	0/0	0/0	1/0	3/1	1/1	60/60
4) Oropharynx	198/198	20/22	23/20	6/3	7/4	1/2	4/2	4/7	0/0	273/268
5) Hypopharynx	214/216	19/26	62/42	1/14	19/15	2/6	4/8	13/12	0/4	384/376
6) Larynx	296/278	5/8	16/16	8/19	10/14	5/4	4/13	8/13	3/3	283/276
7) Major salivary glands	69/70	1/1	1/2	0/1	0/2	0/0	1/0	1/2	1/0	86/83

Nasal cavity, etc.: nasal cavity and paranasal sinuses

Number of clinical outcome by primary tumor site

	<u>Survival (%)</u>	<u>Death of primary cancer (%)</u>	<u>Death of other cancer (%)</u>	<u>Death of other disease (%)</u>	<u>Death of unknown cause (%)</u>	<u>Unknown (%)</u>	<u>total (%)</u>
1) Oral cavity	682 (64)	220 (21)	30 (3)	44 (4)	9 (1)	77 (7)	1062
2) Nasal cavity, etc.	90 (44)	68 (33)	5 (2)	3 (1)	1 (1)	38 (19)	205
3) Nasopharynx	57 (55)	29 (28)	1 (1)	3 (3)	0 (0)	13 (13)	103
4) Oropharynx	313 (60)	116 (22)	14 (3)	23 (4)	5 (1)	51 (10)	522
5) Hypopharynx	352 (50)	174 (25)	41 (6)	32 (5)	14 (2)	84 (12)	697
6) Larynx	430 (68)	65 (10)	37 (6)	29 (4)	10 (2)	62 (10)	633
7) Major salivary glands	99 (62)	42 (26)	3 (2)	3 (2)	0 (0)	12 (8)	159

Nasal cavity, etc.: nasal cavity and paranasal sinuses